---
{"dg-publish":true,"permalink":"/2-areas/university/allergic-rhinitis/","tags":["immunology","allerg"],"created":"2023-02-12T22:00:49.455+07:00","updated":"2025-10-06T19:50:13.073+07:00"}
---

## Note
- ใช้ ARIA 2016, ARIA 2019 guideline   
## Pathology & Etiology
- Allergen กระตุ้นการสร้าง IgE แล้วจดจำไว้ พอเจออีกครั้งก็เกิดการแพ้
- IgE จับ allergen จับ mast cell -> หลั่ง cytokines / inflammatory mediators
- เกิด vasodilation / membrane permebility เพิ่ม / มีสารคัดหลั่งต่าง ๆ / histamine ทำให้คัด มีน้ำมูกไหล

## Symptoms & Diagnosis
- คันหู คันจมูก คันหน้า
- น้ำมูก 
- ไอ 
- post nasal drip
- เสียงแหบ 
- nasal polyps
- ได้กลิ่นน้อยลง รสอาหารน้อยลง
- ไซนัสอักเสบได้

## Goal of therapy
- Reducing VAS to controllable and changing the frequency to intermittent.
## Classification
- Intermittent = no more than 4 day/wk OR no more than 4 wk/year
- Persistent =  more than 4 day/wk OR more than 4wk/year
- mild = มีอาการ ไม่ได้กระทบการใช้ชีวิต (normal sleep, life, work, normal daily symptoms)
- moderate-serve = มีอาการ กระทบการใช้ชีวิต 
## Treatment


### Pharmacological Treatment (New ARIA 2019)

#### AccessPharmacy
- caution in elderly with urinary incontinence/ high intraocular pressure/ constipation/ dry mouth
- leukotriene receptor antagonist inhibit cysteinyl leukotriene receptor (inflammatory mediators released from mast cells in allergy)
	- montelukast can be used in children as young as 6 months, however, if age >= years old, INCS are recommended over LTRA

#### Important Takeover points
- oral or IN anti H1 are less effective in controlling symptoms than INCS, however they may be effective in mild-mod or in pt who prefer oral medication
- Oral vs IN anti H1 shown differ, but cannot draw conclusion
- INCS takes time for response
- azelastine has H1 antagonism + mast-cell stabilizing properties (prevent release of cytokines related with allergy) + reduced concentration of substance P and bradykinin in nasal secretions leading to decreased sneezing and nasal itchin
#### Important clinician key
- monotherapy with INCS rather than INCS + oral antiH1
- recommend INCS over LTRA in age >= 15 years old
- for mod to severe, INCS + IN antihistamine may be recommended
#### Most important pitfall from RWE
- adherence is poor
- patient treat themselves as needed, enhance their therapy and decrease by themselves but concomitant of arbitrary (ตามใจคนไข้ based on random choice or personal whim) combination of various medication does not improve symptom-control
- patient don't follow guideline recommendation
- MPAzeFlu is superior to INCS and is superior to oral antihistamine 1

#### Untreated Patient
- VAS < 5/10
	- 1st line medication
		- Oral anti H1
		- IN anti H1
		- INCS
		- LTRA
		- INCS + (Azelastine) AZE
- VAS >= 5/10
	- Intermittent rhinitis: any suitable therapy
	- Persists ant rhinitis: INCS or INCS+AZE
- Follow-up daily 48-72 h
	- if VAS < 5/10
		- symptomatic: continue treatment
		- not symptomatic: consider step-down or stop
	- VAS >= 5/10
		- step-up and reassesment up to 48-72 hr

#### Stepping up
- Step up to INCS or INCS + AZE
	- if VAS < 5/10 then
		- symptomatic: continue treatment
		- not symptomatic: consider step-down or stop
	- if VAS >= 5/10 then step-up ถ้าไม่ได้แล้ว referral to allergist and AIT



### Pharmacological Treatment (Old)
- Mild Intermittent
	- H1 Blocker เมื่อมีอาการ
- Moderate-Severe Intermittent OR Mild Persistent
	- ใช้ยาเหมือน Mild Intermittent หรือ
	- Nasal Corticosteroid พ่นข้างละ 64 mcg per puff โดยไม่เกิน 256 mcg
		- เด็ก 6-11 ไม่เกิน 128 mcg/day
- Moderate-Severe Persistent
	- Nasal Corticosteroid
refer to: [[2 Areas/University/Antihistamine\|Antihistamine]]

### Non-Pharmacological Treatment
- 

### Patient Education
- 

## Monitoring
- 